Our history
The finest moments in a cancer researcher’s life are when all pieces fall into place. An insight. A connection. A molecule that lands just right.
The finest moments in a cancer researcher’s life are when all pieces fall into place. An insight. A connection.
A molecule that lands just right.
One such moment occurred when our founder, Professor Bengt Gustafsson, together with researchers at Merck & Cie, identified a new path forward — one that could enhance the efficacy of established cancer treatments.
The result was arfolitixorin: a patented drug candidate with the potential to change the treatment landscape. The spirit of discovery that led to arfolitixorin lives on in everything we do. With science as our compass and risk awareness guiding every step, we strive to help more patients respond better to treatment, improve their prognosis, and gain more time with life.
Together, we are making tomorrow’s cancer treatment better.
From 2008 to now
2025
A new phase Ib/II clinical study with an optimized dosing regimen is initiated in Germany.
Rights issue.
New graphic identity.
2024
A new development plan for arfolitixorin, based on a comprehensive evidence platform consisting of analyses and studies, was presented and showed that a new dosage regimen could lead to better results.
Solasia intensified its commitment to the continued development of arfolitixorin and plans to expand the upcoming clinical study in Japan.
Collaboration agreement signed with the world-leading hospital, Charité – Universitätsmedizin Berlin, to conduct the phase Ib/II clinical study in Germany.
2023
Initiated detailed analysis of the AGENT study outcome and possible way forward for the drug candidate arfolitixorin.
2022
Analysis of the study data in the AGENT study begins on April 22.
Final data showed that arfolitixorin did not meet either the primary endpoint or the key secondary endpoint.
2021
Rights issue.
Isofol’s share is listed on Nasdaq Stockholm.
Receives Fast Track Designation.
2020
New share issue.
The global phase III study, AGENT, with arfolitixorin begins in Japan.
Licensing agreement signed with Solasia Pharma K.K. in Japan.
Licensing agreement signed with Paladin in Canada.
The AGENT study fully enrolled with 440 patients.
2018
The global phase III study, AGENT, with arfolitixorin begins in the US and Europe.
2017
Isofol’s share is listed on Nasdaq First North Premier Growth Market.
2016
Regulatory support from FDA and EMA.
2013
Signing of license agreements with Merck, and initial partnership with Recipharm.
2011
Clinical study begin.
2008
The company was founded by Prof. Bengt Gustavsson based on a research collaboration between him and Merck & Cie, the world’s leading manufacturer of folate-based therapies.
Last updated: